Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

198P - Association between BTLA polymorphisms and NSCLC risk

Date

03 Apr 2022

Session

Poster Display session

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Anna Andrzejczak

Citation

Annals of Oncology (2022) 33 (suppl_2): S117-S121. 10.1016/annonc/annonc858

Authors

A. Andrzejczak1, A. Partyka1, A. Wisniewski1, I. Porebska2, K. Pawelczyk3, M. Jasek1, L. Karabon1

Author affiliations

  • 1 Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw/PL
  • 2 Wroclaw Medical University, Wroclaw/PL
  • 3 Lower Silesian Centre of Lung Diseases, Wroclaw/PL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 198P

Background

Importance of immune checkpoints molecules in NSCLC was proven by the introduction of blockade of these receptors in routine treatment. B and T lymphocyte attenuator (BTLA) is another immune checkpoint molecule that regulates immune response. Our previous studies showed a significant association between BTLA gene variants and susceptibility to renal cell carcinoma and chronic lymphoblastic leukemia. The aim of this study was to verify the hypothesis that BTLA polymorphic variants are associated with susceptibility to NSCLC.

Methods

Genomic DNA was isolated from the venous blood of 384 patients diagnosed with NSCLC and 475 controls. Using TaqMan probes we genotyped seven BTLA SNPs: rs1982809, rs1844089, rs9288952, rs9288953, rs2705511, rs2633582, and rs11921669 on ViiA 7 Real-Time PCR System.

Results

Statistical analysis of genotypes and alleles distributions for all investigated BTLA SNPs showed that SNP rs1982809 may be associated with susceptibility to NSCLC. In particular presence of G allele at rs1982809 (AG+GG genotypes) was more frequent in NSCLC group compared to controls (38.8% vs 45.3%, p=0.056). Allele distribution showed that the presence of allele G in rs1982809 significantly increases NSCLC risk (OR=1.25, p=0.046). For other studied SNPs in the overall analysis, we did not observe differences between NSCLC patients and controls. However, in the subgroup analysis we found that in patients with adenocarcinoma (AD) genotypes distribution of rs1982809 was significantly different between AD patients and controls (p=0.048). Moreover, we noticed the trend for overrepresentation of rs2705511[C] allele (AC+CC genotypes) in patients with AD compared to controls (43.4% vs 53%, p=0.079). After stratification by gender, we observed an association between the presence of rs9288953[T] and NSCLC susceptibility (p=0.004) in females. The global distributions of the haplotypes did not differ significantly between the cases and controls. However, we noticed that the global distribution of the haplotypes differs significantly between the never-smokers and smokers (p=0.0003).

Conclusions

Results of our study show that rs1982809 in BTLA gene might be considered a low penetrating risk factor for NSCLC susceptibility in the Polish population.

Legal entity responsible for the study

Laboratory of Genetics and Epigenetics of Human Diseases.

Funding

National Science Center Poland OPUS17 2019/33/B/NZ5/03029.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.